7:50 am Coffee & Registration

8:50 am Chair’s Opening Remarks

  • Simon Robson Professor of Medicine & Anesthesiology, Harvard Medical School, Scientific Founder Purinomia

Exploring the Adenosine-Pathway Targeted Cancer Immunotherapy Preclinical Model Landscape

9:00 am Targeting the Adenosine-Pathway for Cancer Immunotherapy


• Emerging clinical data with oleclumab (anti-CD73 mAb) in combination with various agents across tumor types

9:30 am Dual A2aR/A2bR Antagonism with Etrumadenant Blocks the Immunosuppressive Effects of Adenosine & Enhances Anti-Tumor Immune Responses


  • Exploring the preclinical characterization of dual A2aR/A2bR antagonist etrumadenant
  • Investigating A2aR selective vs dual A2aR/A2bR antagonism in adenosine-mediated suppression of myeloid cell activity

10:00 am Targeted Inhibition of Adenosine-Pathway by Humanized Antibodies to Enhance the Cancer Immunity


• Understanding the rationale of the target

• Highlighting the developing products and combination with checkpoint inhibition

• Discussing the challenges for clinical development

10:30 am Morning Break & Networking

11:15 am Preclinical Studies of PT199, a Humanized mAb That Fully Inhibits Both Membrane Bound & Soluble Serum CD73

  • Hui Zou Chief Scientific Officer, Phanes Therapeutics


• Discussing why the full inhibition of the enzyme activity from both membrane and soluble CD73 is crucial to achieve clinical activity

• Exploring how the PD response/biomarker may guide the selection of targeted indications and/or patients

11:45 am Dual Blockade of Adenosine and PD-1 Immunosuppression Enhances Chimeric Antigen Receptor T-Cell Therapy

  • Phil Darcy Group Leader, Cancer Immunotherapy Laboratory, Peter MacCallum Cancer Centre


• Highlighting immunosuppression within the tumor microenvironment is a major reason underlying poor responses of CAR T-Cell responses in solid tumors

• Showing that dual blockade of adenosine and PD-1 checkpoint pathways significantly enhances CAR T-cell anti-tumor responses in preclinical models

12:15 pm Lunch

1:15 pm INT-1B3 Effectively Modulates the Adenosine Cloud & Induces Immunogenic Cell Death in Preclinical Tumor Models: Opportunities for Translational Medicine


• Illuminating miRNA mimics as novel drugs for therapeutic intervention in oncology

• Discovering the importance of impacting the adenosine cloud for modulation of the immunosuppressive tumor microenvironment

• Navigating the preclinical to clinical transition of adenosine immuno-oncology

1:45 pm Panel Discussion: Discussing the Various Ways to Target the Adenosine- Pathway to Increase Cancer Immunotherapy Efficiency


• Highlighting the benefits and challenges of targeting one enzyme over another

• Exploring targeting a particular receptor over another for effective cancer immunotherapy

Discussing the Clinical Trial Landscape & Clinical Updates Of Drugs in Development Against Adenosine-Pathway Targets

2:15 pm Mupadolimab: A B Cell Activating Anti-CD73 Antibody for Immunotherapy of Cancer & Viral Diseases


• Highlighting that Mupadolimab is a humanized anti CD73 antibody that activates B cells leading to expression of CD69, trafficking to lymph nodes and differentiation into antigen specific plasma cells and memory B cells

• Demonstrating how the antibody has shown preliminary evidence of anti-tumor activity both as monotherapy and in combination with anti-PD1 in patients with nonsmall cell lung cancer and head and neck cancers

• Understanding how treatment of patients with COVID 19 with Mupadolimab has led to sustained high titers of antiviral antibodies

• Discussing the mechanism of action of Mupadolimab and its use in ongoing cancer clinical trials

2:45 pm Targeting the A3 Adenosine Receptor for the Treatment of Advanced Liver Cancer

  • Pnina Fishman Chief Executive Officer & Chief Scientific Officer, Can-Fite BioPharma


• Understanding the rational of targeting the A3 adenosine receptor for the treatment of liver cancer

• Utilizing the highly specific A3 adenosine receptor agonist namodenoson to inhibit liver cancer growth

• Exploring the phase 2 study data and the phase 3 pivotol study protocol

3:15 pm Afternoon Break & Networking

Assessing the Immunotherapy Armamentarium to Select Your Combination Approach

3:45 pm IPH5301, A Differentiated Therapeutic Antibody Targeting Membrance & Soluble CD73, Unleash Anti-Tumor Immune Response In Combination With Cancer Therapies

  • Carine Paturel Senior Director, Program & Portfolio Strategy, Innate Pharma


• Demonstrating IPH5301 differentiated Mode of Action on both membrane and soluble CD73, resulting in optimal restoration of immune response

• Highlighting preclinical safety and activity for IPH5301 in animal models

• Discussing First in Human phase 1 trial

4:15 pm HBM1007, A Fully Human CD73 Antibody With Allosteric Inhibition & Strong Internalization Mediated Target Downregulation For Cancer Therapy


• Highlighting HMB1007 binds to a unique epitope of CD73 and shows high binding affinity to human and Cyno CD73

• Understanding HBM1007 demonstrates irreversible CD73 enzymatic blocking activity and induces CD73 endocytosis and degradation

• Divulging that HBM1007 achieves synergistic anti-tumor efficacy with anti-PD-1 or anti-CTLA-4 Abs

• HBM1007 shows good safety and developability profile

Translating Key Fundamental Learnings from Non-Cancer Adenosine Biology to Inform Cancer Adenosine Biology

4:45 pm Therapeutic Targeting of Hypoxia-A2-Adenosinergic Signaling to Improve the Outcomes Oxygen-Ventilated COVID-19 Patients


• Harnessing the A2A adenosine receptor axis to prevent oxygen-mediated exacerbation of inflammation in COVID-19 patients with acute respiratory distress syndrome

• Understanding the tissue-protecting role of hypoxia and adenosine in infectious diseases and COVID-19 and strategies to improve protocols of supplemental oxygenation

5:15 pm Chair’s Closing Remarks

  • Simon Robson Professor of Medicine & Anesthesiology, Harvard Medical School, Scientific Founder Purinomia